Functional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens

Clicks: 285
ID: 268483
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #37 of 111 articles by views in Frontiers in immunology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The malaria genome encodes over 5,000 proteins and many of these have also been proposed to be potential vaccine candidates, although few of these have been tested clinically. RH5 is one of the leading blood-stage Plasmodium falciparum malaria vaccine antigens and Phase I/II clinical trials of vaccines containing this antigen are currently underway. Its likely mechanism of action is to elicit antibodies that can neutralize merozoites by blocking their invasion of red blood cells (RBC). However, many other antigens could also elicit neutralizing antibodies against the merozoite, and most of these have never been compared directly to RH5. The objective of this study was to compare a range of blood-stage antigens to RH5, to identify any antigens that outperform or synergize with anti-RH5 antibodies. We selected 55 gene products, covering 15 candidate antigens that have been described in the literature and 40 genes selected on the basis of bioinformatics functional prediction. We were able to make 20 protein-in-adjuvant vaccines from the original selection. Of these, S-antigen and CyRPA robustly elicited antibodies with neutralizing properties. Anti-CyRPA IgG generally showed additive GIA with anti-RH5 IgG, although high levels of anti-CyRPA-specific rabbit polyclonal IgG were required to achieve 50% GIA. Our data suggest that further vaccine antigen screening efforts are required to identify a second merozoite target with similar antibody-susceptibility to RH5.
Reference Key
draper2019frontiersfunctional Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Joseph J. Illingworth,Daniel G. Alanine,Rebecca Brown,Jennifer M. Marshall,Helen E. Bartlett,Sarah E. Silk,Geneviève M. Labbé,Doris Quinkert,Jee Sun Cho,Jason P. Wendler,David J. Pattinson,Lea Barfod,Alexander Douglas,Michael W. Shea,Katherine E. Wright,Simone C. De Cassan,Matthew K. Higgins,Simon J. Draper;Joseph J. Illingworth;Daniel G. Alanine;Rebecca Brown;Jennifer M. Marshall;Helen E. Bartlett;Sarah E. Silk;Geneviève M. Labbé;Doris Quinkert;Jee Sun Cho;Jason P. Wendler;David J. Pattinson;Lea Barfod;Alexander Douglas;Michael W. Shea;Katherine E. Wright;Simone C. De Cassan;Matthew K. Higgins;Simon J. Draper;
Journal Frontiers in immunology
Year 2019
DOI
10.3389/fimmu.2019.01254
URL
https://sciprofiles.com/publication/view/eff2256407e858f198eaf2c49a05aaf6
Keywords
vaccine malaria antigen antibodies blood stage malaria neutralising antibodies merozoite rh5

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.